Litcius/Paper detail

The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria

Lian J. Pennings, Mike Marvin Ruth, Heiman Wertheim, Jakko van Ingen

2021Antimicrobial Agents and Chemotherapy23 citationsDOIOpen Access PDF

Abstract

The parent drug SPR720 could have a role especially in MAC pulmonary disease treatment. Further studies in dynamic models and trials are ongoing to advance clinical development.

Topics & Concepts

Nontuberculous mycobacteriaBenzimidazoleMycobacterium avium complexMedicinePulmonary diseasePharmacologyMicrobiologyMycobacteriumTuberculosisIntensive care medicineInternal medicineBiologyChemistryPathologyOrganic chemistryMycobacterium research and diagnosisTuberculosis Research and EpidemiologyQuinazolinone synthesis and applications
The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria | Litcius